This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Symtuza
  • /
  • A Study to Evaluate the Efficacy and Safety of (D/...
Clinical trial

A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Tr

Read time: 3 mins
Last updated:31st Jul 2017
Identifier: NCT03227861

Brief Summary:
The purpose of this study is to assess the efficacy of Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF) fixed-dose combination (FDC) in a Test and Treat model of care in newly diagnosed human immunodeficiency virus (HIV-1)-infected, treatment-naive participants as determined by the proportion of virologic responders defined as having (HIV)-1 ribonucleic acid (RNA) lesser than 50 copies per milliliter (copies/mL) at Week 48.


Study Type: Interventional  (Clinical Trial)
Actual Enrollment: 109 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3, Single-arm, Open-label Study to Evaluate the Efficacy and Safety of Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF) Once Daily Fixed-dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naïve Human Immunodeficiency Virus Type 1 (HIV-1) Infected Subjects Receiving Care in a Test and Treat Model of Care
Actual Study Start Date: July 31, 2017
Estimated Primary Completion Date: December 31, 2018
Estimated Study Completion Date: December 31, 2018

Arm:
- Experimental:
DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC

Category Value
Date last updated at source 2018-05-30
Study type(s) Interventional
Expected enrolment 109
Study start date 2017-07-31
Estimated primary completion date 2018-12-31

View full details